StageOne Ventures

StageOne Ventures sits in the unglamorous middle of the digital health stack, funding the cloud, data, and AI infrastructure that other companies’ patient-facing apps end up running on. The fund operates out of Herzliya and writes checks at Seed and Series A into Israeli B2B enterprise software companies, with a clear preference for teams whose product spends most of its life behind an API rather than in front of a clinician.

The thesis is straightforward. Modern digital health platforms are heavy on integrations, model serving, observability, and data pipelines, and most of those layers are still being rebuilt for healthcare’s specific compliance and reliability constraints. StageOne backs the founders building those layers rather than the application companies on top. That extends naturally into AI/ML in healthcare and broader health IT, where the firm is comfortable with unsexy categories like middleware, MLOps for clinical models, and data tooling for hospitals and payers. The fund is genuinely AI-native rather than AI-adjacent, which matters when the pitch involves model evaluation, retrieval, or inference cost economics.

Checks land in the one to five million dollar range, typically as a lead or co-lead at Seed, with selective Series A participation when an existing portfolio company graduates or a new opportunity fits. Geography is anchored to Israel, with a strong bias toward founders selling into US enterprise customers from day one. StageOne is comfortable being the first institutional money in and is also comfortable sitting alongside larger funds when a round demands it. The fund expects defensible technical moats, real design partners, and a credible path from pilot to multi-year contract rather than a single hospital reference.

The partnership is small and operates without the layered associate structure that slows down most institutional funds. Founders deal directly with partners on diligence and post-investment support, and decisions move on a timeline closer to a seed fund than a multi-stage platform. That suits the kind of technical founder StageOne tends to back, who usually wants substantive feedback on architecture and go-to-market rather than process.

In practice, the fund’s value-add concentrates on enterprise sales mechanics: navigating procurement at US health systems and life sciences buyers, structuring early contracts so the unit economics survive scaling, and helping founders avoid the trap of one-off custom builds that look like revenue but aren’t. StageOne is candid about what it cannot do. It is not a deep clinical network and does not pretend to replace one, so founders building therapeutics or device-heavy companies should look elsewhere. For a B2B infrastructure or AI software company targeting healthcare and life sciences buyers, though, it is one of the more direct conversations a Seed-stage Israeli founder can have. Expect a focused diligence process, an emphasis on technical depth and customer evidence over narrative, and a partner who will engage with the actual product rather than a slide on TAM. Founders who want a hands-off check that simply shows up at board meetings will find the engagement model heavier than they expected; founders who want a partner who reads the docs will find it about right.